News Articles

      • 13 March, 2019

    ISSCR Applauds New Japanese Rules Allowing Human-to-Animal Chimeric Embryo Research

    The ISSCR supports research using human-animal chimeras conducted under appropriate review and oversight (ISSCR Guidelines Recommendation 2.1.5) and applauds the new Japanese rules enabling research on chimeric embryos.
    Full story
      • 11 March, 2019

    ISSCR 2019 Election Results

    ISSCR has elected its next leadership slate, with leaders beginning their terms after the 2019 annual meeting. On behalf of all members, we extend congratulations to newly-elected officers Melissa Little, vice president; and Kenneth Zaret, treasurer, and re-appointed board members Marianne Bronner, Valentina Greco, and Arnold Kriegstein.
    Full story
      • 25 February, 2019

    Progress in Stem Cell Science & Regenerative Medicine On Tap in Los Angeles, 26-29 June

    Top scientists and researchers from academia, medicine, and industry will gather to share groundbreaking stem cell science and its translation to clinical application at the annual meeting of the International Society for Stem Cell Research (ISSCR), 26-29 June in Los Angeles, Calif.
    Full story
      • 8 February, 2019

    ISSCR Announces 2019 Award Recipients

    The ISSCR announces the recipients of its 2019 Award for Innovation, Dr. Susan Lim Award for Outstanding Young Investigator, Tobias Award Lecture, and Public Service Award. Awardees will be recognized at the ISSCR annual meeting, 26-29 June, in Los Angeles, Calif., U.S.
    Full story
      • 21 January, 2019

    ISSCR Introduces Chief Operating Officer Keith Alm

    Keith Alm joined the ISSCR as chief operating officer in January 2019, after serving as a brand strategist and consultant for the society for nearly a decade. He’s worked with many of the organization's leaders on strategic positioning, communications, and partnerships.
    Full story
      • 13 December, 2018

    ISSCR Testimony in U.S. Congress Regarding Need for Fetal Tissue Research

    In written and oral testimony before the U.S. House of Representatives Oversight and Government Reform Committee today, former ISSCR president Sally Temple describes fetal tissue research as essential in studying and developing therapies for cancer, HIV, Zika, tuberculous, and other devastating diseases.
    Full story
      • 26 November, 2018

    ISSCR Comments on Reports of Chinese Scientists Performing Genome-Editing During Fertility Treatment

    Reports indicate that scientists in China have used CRISPR-mediated genome editing during in vitro fertilization to modify the genetic material of two embryos that were subsequently implanted into a patient, leading to the birth of two babies. As ISSCR and a number of other organizations have previously stated, the use of nuclear genome editing technologies, such as CRISPR, during fertility treatment is premature and should not be attempted at this time.
    Full story
      • 16 November, 2018

    ISSCR Applauds FDA, FTC for Holding Deceptive Stem Cell Clinics Accountable

    The U.S. Food and Drug Administration has issued a warning letter to StemGenex of San Diego after an investigation found its cellular therapy does not conform with good manufacturing practice requirements, is being illegally marketed to treat conditions for which it has not been proven safe or effective, and is putting patients at risk.
    Full story
      • 2 October, 2018

    ISSCR Comments on Horizon Europe

    The ISSCR has responded to the European Commission proposal and the European Parliament's amendments for Horizon Europe, the seven-year research and innovation funding program to follow Horizon 2020.
    Full story
      • 27 September, 2018

    ISSCR Responds to U.S. Department of Health and Human Services Decision Regarding Fetal Tissue Research

    The ISSCR is troubled by the HHS decision to “conduct a comprehensive review of all fetal tissue research.” The directive appears to come after intensive lobbying efforts by special interest groups with the goals of delaying or curtailing scientific research that relies on fetal tissue.
    Full story
      • 22 June, 2018

    Douglas A. Melton Becomes President of the ISSCR

    The ISSCR is pleased to announce Douglas A. Melton, PhD, Harvard University, as the incoming president of the ISSCR and its board of directors. Melton assumed the post on 23 June, 2018, immediately following the 16th ISSCR Annual Meeting in Melbourne, Australia.
    Full story
      • 20 June, 2018

    ISSCR Announces New Editor-in-chief for Stem Cell Reports Journal

    The ISSCR has appointed Martin F. Pera, professor at the Jackson Laboratory, U.S., as the next editor-in-chief of Stem Cell Reports, the organization’s open-access journal. Pera will succeed Christine Mummery, who led the journal since its launch in 2013. Pera will assume the post in January, 2019.
    Full story
      • 14 June, 2018

    ISSCR Opposes Proposal to Restrict Fetal Tissue Research

    The ISSCR opposes the U.S. House of Representatives proposal to ban federal funding for fetal tissue research. ISSCR President Hans Clevers released a statement on the issue.
    Full story
      • 23 May, 2018

    ISSCR Announces Hamburg, Germany as Site of 2021 Annual Meeting

    The ISSCR will hold its 2021 annual meeting in Hamburg, Germany, the first time the organization will be meeting in that city. The meeting is expected to draw 4,000 stem cell researchers and professionals from around the globe to the Congress Center Hamburg, scheduled to open in 2019. The meeting will be held 23-26 June, 2021.
    Full story
      • 4 June, 2018

    ISSCR Responds to President Trump Signing 'Right to Try' Law

    The ISSCR is disappointed with the enactment of the ‘Right to Try’ law. Along with more than 100 patient and research groups opposing the bill, we believe it will put patients at risk and undermine the effective FDA Expanded Access Program already in place to give seriously ill patients access to experimental treatments.
    Full story